CKD Bio Corp. Corporate Governance Report: 9 out of 15 Key Indicators Met, Lacks Dividend Predictability and Internal Audit Expertise, Highlighting Governance Improvement Tasks
CKD Bio Corp. disclosed its corporate governance report for FY2025, meeting 9 out of 15 core indicators (60%), acknowledging deficiencies in 6 items including lack of dividend predictability.
In FY2025, consolidated revenue was 160.07B KRW, operating profit 0.36B KRW, and net loss 0.289B KRW. In FY2024, a cash dividend of 100 KRW per share (0.5% yield) was paid, but no dividend for FY2025.
The board comprises 2 inside directors, 1 non-executive director, and 1 independent director (female); no board committees due to assets under 2 trillion won.
Internal audit is performed by a full-time auditor without a separate internal audit department or accounting/finance expert, limiting expertise.
No medium-to-long-term shareholder return policy exists, creating dividend uncertainty; also, no written voting system, limiting shareholder voting accessibility.
CEO succession policy (established Sep 2025), risk management, and internal control policies are in place; quarterly meetings with external auditors are held.
[AI Summary]CKD Bio Corp. meets legal governance standards, but improvements in dividend policy transparency and internal audit expertise are needed to enhance shareholder value.